XW143H9
Transfusion Central Vein to New Technology Group 9 with Lovotibeglogene Autotemcel, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 1 Transfusion |
| Body Part | 4 Central Vein |
| Approach | 3 Percutaneous |
| Device | H Lovotibeglogene Autotemcel |
| Qualifier | 9 New Technology Group 9 |
Operation Definition
Putting in blood or blood products
Procedure Overview
This family applies specifically to putting blood or blood products into a patient using a New Technology-designated product, distinguishing it from routine transfusions of standard blood components. It exists because certain newer blood-derived products, engineered or processed differently from conventional units, are tracked separately to monitor their use and outcomes.
A patient receiving this kind of transfusion is usually being treated for a condition where standard blood products have proven insufficient, such as certain bleeding disorders or infections, and the care team has opted for a product with novel approval status.
Anatomy & Axis Detail
Central Vein
When a New Technology transfusion product is delivered through a central vein, such as the superior vena cava, subclavian, or internal jugular approach to a central line, this code reflects that the therapy required central venous access rather than a peripheral limb vein. Central administration is typically chosen for products that are more concentrated, require rapid systemic distribution, or are irritating to smaller peripheral vessels, and it is also used when a patient already has a central line in place for other care. Because central venous catheterization itself carries risks like pneumothorax or catheter-related infection, documentation should confirm both the venous access site and the specific novel product transfused. Coding must distinguish this central-vein pathway from the peripheral-vein version of the same New Technology substance to reflect the different access route and associated risk profile.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Lovotibeglogene Autotemcel
Lovotibeglogene autotemcel (marketed as Lyfgenia) denotes administration of an autologous hematopoietic stem cell gene therapy that adds a modified beta-globin gene to treat sickle cell disease and reduce vaso-occlusive events. It differs from exagamglogene autotemcel, which achieves a similar clinical goal through CRISPR gene editing rather than viral vector gene addition, and from betibeglogene autotemcel, which targets beta-thalassemia.
Qualifier: New Technology Group 9
Group 9 is the seventh-position qualifier used in the New Technology section to mark a device, substance, or technique as belonging to the 2022 annual cohort of new technology add-on codes. It has no clinical meaning of its own beyond that vintage tag, so coders rely on the specific table and body system to know what procedure it applies to. It is distinguished from Group 8 and Group 10 purely by the fiscal year the technology was approved for separate identification.
Coding & Documentation
The documentation needs to specify the exact blood product given, since this family is tied to specific New Technology-approved products rather than blood transfusion in general. Coders should confirm the product name against current approval lists before assigning a code here rather than to a standard transfusion code.
The most common mistake is coding a novel-sounding product under routine transfusion codes, or conversely, assuming any unfamiliar blood product automatically belongs in this family without checking that it actually holds New Technology status.
Commonly Confused With
This is easily confused with standard blood transfusion codes found in the Administration section. The difference comes down entirely to whether the specific product administered has been given New Technology recognition, not the clinical reason for the transfusion or the route used.